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Background – The microbiology laboratory can be perceived as a service provider rather than an integral part of
the healthcare team.
Objectives – The aim of this review is to discuss the current challenges of providing a state-of-the-art diagnostic
veterinary microbiology service including the identification (ID) and antimicrobial susceptibility testing (AST) of
key pathogens in veterinary dermatology.
Methods – The Study Group for Veterinary Microbiology (ESGVM) of the European Society of Clinical Microbiol-
ogy and Infectious Diseases (ESCMID) identified scientific, technological, educational and regulatory issues
impacting the predictive value of AST and the quality of the service offered by microbiology laboratories.
Results – The advent of mass spectrometry has significantly reduced the time required for ID of key pathogens
such as Staphylococcus pseudintermedius. However, the turnaround time for validated AST methods has
remained unchanged for many years. Beyond scientific and technological constraints, AST methods are not har-
monized and clinical breakpoints for some antimicrobial drugs are either missing or inadequate. Small laborato-
ries, including in-clinic laboratories, are usually not adequately equipped to run up-to-date clinical microbiologic
diagnostic tests.
Conclusions and clinical importance – ESGVM recommends the use of laboratories employing mass spec-
trometry for ID and broth micro-dilution for AST, and offering assistance by expert microbiologists on pre- and
post-analytical issues. Setting general standards for veterinary clinical microbiology, promoting antimicrobial
stewardship, and the development of new, validated and rapid diagnostic methods, especially for AST, are
among the missions of ESGVM.
Introduction
In veterinary medicine, the microbiology laboratory is per-
ceived as a service provider rather than an integral part of
the healthcare team, resulting in limited interaction
between microbiologists and clinicians. This differs from
human medicine, where microbiologists interact with
infectious disease specialists to provide advice on antimi-
crobial therapy, infection control, antimicrobial steward-
ship practices, antimicrobial resistance trends and
compliance with antimicrobial guidelines. The use of
diagnostic microbiology is comparatively lower than in
human medicine, although differences exist between
countries and veterinary practices.1 This difference is
attributable to structural, economic and cultural factors
that differentiate the veterinary healthcare system from
the human counterpart. The limited utilization of microbi-
ology tests in veterinary practice has negative conse-
quences on the costs, with these being as much as three
times higher than the costs of comparable tests in the
human healthcare sector. Formal antimicrobial steward-
ship programmes, which traditionally involve microbiol-
ogy laboratories in human hospitals, are rarely
implemented by veterinary clinics.2 Antimicrobials are
mainly used empirically and the use of antimicrobial sus-
ceptibility testing (AST) is generally limited to difficult
cases with poor response to initial therapy.1 This trend is
unfortunate given the current concerns regarding antimi-
crobial use and emergence of multidrug-resistant bacteria
in animals, including companion animals.3 Use of culture
and AST to guide antimicrobial choice is recommended
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by numerous guidelines on responsible antimicrobial use
developed by governmental, animal health and veterinary
organizations, including the European Commission,4 the
World Organization of Animal Health (OIE)5 and the Amer-
ican Veterinary Medical Association (AVMA).6 As demon-
strated in human medicine, implementation of
antimicrobial stewardship at the clinic level has positive
consequences on appropriate antimicrobial use, control
of antimicrobial resistance and patient care.7
Quality and quality control are important in clinical
microbiology. International standards8,9 and manuals10,11
for clinical microbiology are available but their use is, for
the most part, voluntary, although some guidelines have
been adopted by accrediting organizations as part of their
accreditation requirements. Uniform guidelines for best
practice are not widely available for veterinary clinical
microbiological laboratories; in general, accredited labo-
ratories have implemented the guidelines for human
clinical microbiology laboratories. Furthermore, there is
an increasing trend for veterinary clinics to perform in-
house microbiology. Despite the advantages of reduced
turnaround time and costs, there are also disadvan-
tages and risks associated with this practice. The
microbiological expertise required to accurately perform
and interpret the diagnostic tests, as well as to perform
routine quality control and manage the biohazard risks,
are lacking in most in-clinic and small diagnostic labora-
tories.
The aim of the Study Group of Veterinary Microbiology
(ESGVM), established within the European Society for
Clinical Microbiology and Infectious Diseases (ESCMID),
is to promote state-of-the-art veterinary clinical microbiol-
ogy. This review highlights some of the current chal-
lenges in veterinary microbiology and outlines the quality
standards required with particular reference to veterinary
dermatology.
State-of-the-art methodologies
Microbe identification
Classic culture-based methods have been the mainstay
of clinical microbiology for the past century. Automated
systems are being implemented, but to date most of
these technologies rely on pure culture of the micro-
organism. Identification (ID) of the micro-organism is an
important prerequisite before AST to distinguish between
potentially pathogenic micro-organisms and possible con-
taminants from the commensal microbiota on nonsterile
body sites. Microbial ID has traditionally been performed
by testing biochemical properties of the micro-organism.
A step forward was achieved with the development of
standardized commercial test systems (e.g. API or
rapIDTM), which have gradually replaced the use of in-
house tube tests, enabling diagnostic laboratories to use
a validated manual system without expensive hardware.
The next step was to offer these tests in more or less
automated versions to avoid subjective interpretation
(e.g. VITEK Systems, BD PhoenixTM Automated Sys-
tems, TREK Sensititre Diagnostic Systems). The quality
of these systems in veterinary microbiology is strongly
dependent on the databases used. Species found com-
monly in human microbiology, such as Pseudomonas
aeruginosa, are well represented within the databases of
these ID systems and therefore reliably identified. How-
ever, some species of veterinary relevance, including Sta-
phylococcus pseudintermedius and Staphylococcus felis,
are very difficult to reliably identify and differentiate from
closely related staphylococci. Additionally, as the bio-
chemical activity of a strain depends on growth, micro-
organisms that do not grow in these systems cannot be
identified (e.g. some members of Pasteurellaceae) and
the ID may not be reliable for some micro-organisms (e.g.
Malassezia) if the patient is under treatment with antimi-
crobials at the time of specimen collection.
New technologies have been introduced in recent
years to overcome the disadvantages of biochemical ID.
One technology that has gained increasing attention in
veterinary microbiology is MALDI-TOF (matrix-assisted
laser desorption/ionization-time of flight) mass spectrom-
etry (MS) (Figure 1). This technique identifies any cultur-
able bacteria within minutes and has low running
costs.12,13 For most fungi a somewhat more complex
sample preparation is necessary, but even dermato-
phytes can be identified with this method within 2 h.
Again, identification depends on database entries, but the
ability to discriminate between different bacteria is gener-
ally very good for most species. In general, the available
databases are much broader than any of the former bio-
chemistry based databases, but still some veterinary
specific entries are lacking. The databases are updated
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Figure 1. Principle of the MALDI-TOF (matrix-assisted laser desorp-
tion/ionization-time of flight) MS process. For most bacteria a simple
direct smear preparation onto a target plate is covered by a matrix
solution to enable the generation of ions by a laser. These ions,
derived mainly from the highly abundant proteins of the micro-organ-
ism, are then accelerated and travel through a predefined distance in
a vacuum tube (field free drift range). The time delay of their journey
until the ions reach a detector is measured and displayed according
to the mass of the ions as a characteristic pattern of the proteins
(spectrum) detected in the micro-organism. Identification is then
derived from comparison of the protein profile to database matches.
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regularly and each laboratory can add entries to the data-
base. This approach has been shown to be successful for
the Staphylococcus intermedius group (SIG), which is of
special importance in the field of dermatology.14 Of
course, a prerequisite for database expansions are strict
protocols for quality control that must be followed to
ensure highly reliable entries. In general, confirmation of
the respective strains by sequencing before addition to
the database is necessary. In human medicine, MALDI-
TOF MS is used for direct ID of bacteria in blood
cultures.15 Similar applications for direct ID in veterinary
clinical specimens have not yet been developed. The
main disadvantage of this technology is the high cost for
purchasing and servicing the instrument, which makes it
unaffordable by small diagnostic laboratories. However,
the actual cost of the test is extremely low and alliance
between laboratories may be used to make this technol-
ogy accessible without every laboratory buying the
instrument.
Another technology, DNA sequencing, is widely used
as a research tool to investigate bacterial evolution and
molecular epidemiology; at the time of writing this is not
frequently employed in routine clinical microbiology.
Recently, more advanced sequence-based techniques
have become available.16 Isolated and purified micro-
organisms can be identified by Whole Genome Sequenc-
ing (WGS) over 24 h,17 and publicly available web tools
are available for multi-locus sequence typing (MLST) and
ID of acquired antimicrobial resistance genes using raw
WGS data.18,19 Direct sequencing of DNA extracted from
clinical specimens enables bacteria ID in polymicrobial
samples and reduces diagnostic times to 24 h.20 DNA
sequencing technologies are rapidly evolving and becom-
ing more affordable, but widespread implementation in
veterinary microbiology laboratories in the near future
probably is limited to larger laboratories.
Antimicrobial susceptibility testing
Broth micro-dilution and disk diffusion are the most
widely used methods for AST. Broth micro-dilution is the
gold standard method for AST and the only method for
which an internationally accepted ISO standard exists
(ISO 20776-1, 2006).9 The principle of this method is sim-
ple. Broth suspensions containing the test strain are
added to wells containing two-fold dilutions of antimicro-
bials. Upon incubation, the minimum inhibitory concentra-
tion (MIC) is read for each antimicrobial as the lowest
concentration inhibiting visible bacterial growth, and used
for interpretation of susceptibility. The method can be
highly automated and is generally performed using com-
mercial panels with a fixed composition of antimicrobials.
Disk diffusion, also known as the Kirby–Bauer method, is
performed by streaking broth containing the test strain on
an agar plate followed by applying antimicrobial-impreg-
nated disks. Upon incubation, inhibited bacterial growth
around each disc is measured as a zone diameter and
used for interpretation of susceptibility. This method is
cheaper and more flexible than broth micro-dilution, as
the user can easily change the antimicrobials between
tests. It is, however, less robust and reproducible, and
semi-quantitative in nature as it only indicates whether
the test strain is susceptible (S), intermediate (I) or
resistant (R). Laboratories have to select the most appro-
priate antimicrobials for routine AST based on bacterial
species, breakpoint availability, animal species, infection
site and available guidelines. The major shortcoming of
both methods is turnaround time (approximately 48 h)
from culture of the clinical specimen to reporting of the
results. Both methods must be performed following qual-
ity standards (e.g. inoculum density and size, media, incu-
bation conditions, etc.) that are set by two international
committees; namely the European Committee on Antimi-
crobial Susceptibility Testing (EUCAST) and the Clinical
and Laboratory Standards Institute (CLSI), and various
national committees. To date, only CLSI provides clinical
breakpoints and interpretive criteria for veterinary patho-
gens.21 A veterinary subcommittee of EUCAST (Vet-
CAST) recently has been established with the purpose of
harmonizing AST in Europe as well as on a global scale
(http://www.eucast.org/organization/subcommittees/ve
tcast/).
Alternative technologies are currently being evaluated
to reduce the turnaround time of AST. Real-time PCR
assays have been developed for rapid detection of resis-
tant bacteria of high clinical relevance such as meticillin-
resistant Staphylococcus aureus (MRSA) directly from
specimens.22 MALDI-TOF MS can be employed for rapid
detection of extended-spectrum beta-lactamase (ESBL)-
producing bacteria in blood cultures through quantifica-
tion of b-lactam degradation products.23 Flow cytometry
is a method used for detection of morphological and
metabolic changes of cells, for example upon antimicro-
bial exposure. This method has been tested for rapid AST
of various organisms, and one study demonstrated the
potential for detecting ESBL in 3 h from pure bacterial cul-
tures.24
WGS is not yet as rapid as these two other methods
but offers the advantage of enabling screening of all
known resistance genes by a single analysis, and it
requires little hands-on time. WGS provides information
on the presence of resistance genes, allowing prediction
of antimicrobial susceptibility. High (99.7%) accordance
between pheno- and genotypic resistance was demon-
strated between 200 bacterial isolates belonging to four
different species,19 and the same predicted susceptibility
profiles have been obtained using direct sequencing on
clinical specimens and sequencing of single isolates.20
The disadvantage of WGS is that it fails to reveal as yet
undescribed resistance genotypes, and the actual pheno-
type may not always be deduced from sequencing data.
For example, detection of nonfunctional pseudogenes or
repressed efflux systems may lead to false positive (R)
results.
Point-of-Care testing
Point-of-Care (PoC) tests are diagnostic tests that can be
performed with the patient, therefore reducing turnaround
time. The tests are based on different technologies, pre-
dominantly immunochromatography, agglutination assays
and real-time PCR.25 A rapid immunoassay for PoC detec-
tion of urinary tract infection in dogs (RapidBacTM Vet;
http://www.rapidbacvet.com/) has a high sensitivity
(97.4%) and specificity (98.8%) for identification of clinical
bacteriuria.26 A limited number of commercial PoC tests
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are available for on-site AST in veterinary clinics. A simple
diagnostic system (Speed-BiogramTM; https://www.bvt.fr/
en/home/diagnostic-solutions/pour-le-veterinaire-praticien/
infectious-diseases/main/gamme-speed/speed-biogram-1.
html) has become available and can perform simultaneous
ID and AST on cutaneous and ear specimens within
24–48 h. The main disadvantage is that the inoculum
might be polymicrobial and cannot be standardized, leading
to possible false resistance or false susceptibility reporting,
which may also arise with disk diffusion testing.
Direct AST of clinical specimens (e.g. urine), without
prior isolation of bacterial colonies, has the advantage of
making results available earlier but this is controversial
because of concerns regarding its accuracy. A human
study demonstrated a 93% agreement between direct
and conventional AST.27 The highest percentage of dis-
cordance (13%) was observed for b-lactam antimicrobial
drugs such as amoxicillin clavulanate and cephalosporins.
Similar results have been reported for another PoC test
designed for direct ID and AST of uropathogens (Flexi-
cult Vet; http://www.ssidiagnostica.dk/da/Produkter/
Substrater/Flexicult-Vet-URINKIT).28 In human medicine,
direct AST is recommended only for critically ill patients
and does not replace conventional AST, which is addition-
ally performed to confirm the preliminary results obtained
by direct AST.26 Accordingly, ESGVM recommends that
samples testing positive and strains testing resistant by
PoC tests are sent to accredited laboratories for AST by
validated methods. In some countries (e.g. France), PoC
tests are not permitted for AST of critical antimicrobial
drugs (e.g. fluoroquinolones and higher generation cepha-
losporins) due to test limitations. Conversely, PoC tests
may be useful for rapid detection of negative samples
and susceptible strains, avoiding the time and the cost of
laboratory analysis.
Current challenges in veterinary diagnostic
microbiology
Specimen management
Improper specimen management impacts on both the
diagnosis and outcome of therapy.29 Microbiology labora-
tories should provide information to ensure the appropri-
ate selection, collection, storage and transportation of
clinical specimens. National and international guidelines
provide detailed information on the best sample type,
sampling technique and transport conditions for bacterial
infections. For superficial bacterial folliculitis, pustular
contents and papule biopsies are optimum. Swabs of
crusts and epidermal collarettes result in a higher risk of
contamination with commensal skin surface bacteria.30
For wound infections, the type of specimen and sampling
technique depend on the wound type.30 In general,
biopsy samples obtained after initial debridement and
cleansing are the most useful for determining the micro-
bial load and the presence of relevant pathogens. Fluid
samples obtained by aseptic needle aspiration may be
used for cavity wounds (e.g. pressure sores) and cuta-
neous abscesses. The value of wound swabs even after
cleansing a wound prior to sampling is questionable.31
Visible contamination, however, should be removed
before a sample is collected.
Usually a single lesion is sampled and relatively few
colonies are used by the laboratory for both ID and AST.
Recent studies have demonstrated, however, that multi-
ple strains with distinct antimicrobial resistance profiles
may occur in the same lesion or in different lesions from
the same patient.32,33 Further evaluation to assess the
magnitude and clinical significance of this phenomenon is
indicated. In theory, the involvement of multiple strains
from canine skin infections is plausible given the frequent
carriage of multiple S. pseudintermedius strains in
dogs.34 Primary isolation using commercial selective agar
plates may be performed in addition to nonselective isola-
tion on blood agar to facilitate detection of meticillin-resis-
tant staphylococci occurring at low numbers in mixed
cultures. Unless anaerobic bacteria are being investigated
(e.g. deep wound infections), storage and transportation
of dermatological specimens does not present any speci-
fic challenges, because the main pathogens involved
(Table 1) can survive for several days in transport media.
Nevertheless, sample pickup by courier and overnight
transport offer the advantage of reducing the overall turn-
around time.
Pathogen identification
Bacterial species relevant for common disease conditions
in veterinary dermatology are listed in Table 1. Staphylo-
cocci are the most frequent bacterial pathogens associ-
ated with skin and soft tissue infections. Historically,
Table 1. Performance of biochemistry, including manual and automated methods, and MALDI-TOF MS for species identification of micro-organ-
isms of recognized clinical relevance in veterinary dermatology
Micro-organism Biochemistry MALDI-TOF MS
Staphylococcus pseudintermedius Inadequate Inadequate with standard database
Excellent with extended database
Staphylococcus schleiferi Inadequate Good (no distinction between subspecies)
Staphylococcus aureus Good Excellent
Staphylococcus felis Inadequate Good
ß-haemolytic streptococci Good Good at species level
Inadequate at subspecies level (excellent with extended database)
Pseudomonas aeruginosa Good Excellent
Proteus spp. Good Excellent
Dermatophytes Good Good (M. canis: excellent; Trichophyton spp.: genus level only)
Malassezia spp. Inadequate Good
Candida spp. Inadequate Good
MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight) mass spectrometry (MS).
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animal pathogenic staphylococci have been associated
with coagulase-positive staphylocci (CoPS), whereas
CoNS generally have been regarded as bacteria with low
pathogenic potential. Before the description of S. inter-
medius in 1976,35 all CoPS isolated from animals were
(mis)identified as S. aureus. Subsequently, S. inter-
medius was differentiated into three distinct species:
S. intermedius, S. delphini and S. pseudintermedius
(referred to as the SIG group).36 The latter species is the
normal commensal and opportunistic pathogen of the
dog, even though infections also are reported in cats
and less frequently in other hosts, including humans.37
Staphylococcus pseudintermedius cannot be easily distin-
guished from the other members of the SIG group by
phenotypic methods and its speciation requires PCR-
based tests or MALDI-TOF MS, provided that the data-
base has been specifically refined for identification of this
species (see above).
CoNS are commensal organisms with a relatively high
rate of meticillin-resistance in companion animals.38
CoNS have been regarded as “contaminants” and either
not reported or speciated except when isolated in pure
culture from hospital-acquired infections associated with
surgery or invasive procedures. The recognition of
S. schleiferi 39,40 as a canine pathogen underpins the
importance of identifying CoNS species as the coagulase
activity of this species and subspecies (subspp. schleiferi
and coagulans) is variable. MALDI-TOF MS is superior to
other methods for the identification of this group of
staphylococci.41 ESGVM recommends that AST profiles
for S. schleiferi and other CoNS should only reported
when the organisms are isolated in pure culture from
sterile sites or from intact primary skin lesions sampled
under strict aseptic conditions.
Polymicrobial cultures are common for otitis and
wound infections, and can occur from skin samples. In
these cases, the relevance of the culture result and the
selection of the isolate for AST need to be determined.
The current recommendation for human wound infec-
tions is that growth of potential pathogens should be
reported, preferably semi-quantitatively.30 AST should be
performed when a pathogen is isolated in pure culture
or in abundance with minimal involvement of other
micro-organisms. Antimicrobial therapy should target the
micro-organism with greatest pathogenic potential. Indis-
criminate reporting of AST profiles for micro-organisms of
minimal clinical relevance is discouraged to avoid unnec-
essary use of broad-spectrum antimicrobial drugs to
cover the composite AST profile of multiple isolates.
Lack or inadequacy of clinical breakpoints
A clinical breakpoint (CBP) is the critical MIC (or the corre-
sponding interpretive inhibition zone diameter for disk dif-
fusion) selected by ad hoc international (e.g. CLSl or
EUCAST) or national (e.g. US Food and Drug Administra-
tion) committees to categorize a bacterial strain as sus-
ceptible (S), intermediate (I) or resistant (R). CBPs are
typically established on the basis of microbiological, phar-
macokinetic (PK), pharmacodynamic (PD) and clinical out-
come data.42 The purpose of CBPs is to assist clinicians
to select appropriate drugs for therapy. In vitro AST does
not, however, consider other factors that affect the
outcome of antimicrobial therapy, such as host immune
status, co-morbidities, strain virulence and compliance.
By definition, a strain is reported susceptible to a drug
when the standard dosage regimen is associated with a
high likelihood of therapeutic success (approximately
90% according to human studies). The resistant category
does not unequivocally predict treatment failure but a
reduction of therapeutic success with a cure rate up to
60%. This is referred to as the 90–60% rule in human
medicine.43,44 The clinical predictive value of AST is fur-
ther impacted in veterinary medicine by the lack, or inade-
quacy, of available breakpoints. For example, breakpoints
are unavailable for several antibiotics suitable for the
treatment of skin infections in cats (Table 2). In those
cases a CBP from dogs would typically be used. For bac-
teria or infections without any veterinary CBP, a human-
derived CBP may be employed. This is the case for sul-
phonamides/trimethoprim and antibiotics such as chlo-
ramphenicol or rifampicin used for treatment of MRSA
and meticillin-resistant S. pseudintermedius (MRSP)
infections (Table 2). Cefovecin is a veterinary drug for
which no CBP exist, hence the in vivo efficacy of this drug
is difficult to predict by AST. Clearly, the predictive value
of AST can be severely impacted by the use of inade-
quate CBPs, because a human CBP reflects the dosage
regimen and the PK of the drug in humans, and both
dosage regimen and drug disposition exhibit large differ-
ences between animal species. Reliable CBPs require
animal species-specific determinations and there is an
urgent need for animal-specific CBPs.
CBPs are dosage regimen-dependent because they are
set by PK/PD analysis according to a specific dosage.
Thus, a CBP set for a drug administered twice a day may
not be appropriate if the same drug is administered three
times a day. For example, amoxicillin clavulanate has a
set breakpoint according to a defined dosage regimen
[11 mg/kg per os (PO) twice daily],21 even though an
increased dose according to label recommendations
(12.5–25mg/kg PO twice daily) can be used and three
doses a day are recommended by international guidelines
for treatment of urinary tract infections.45 Similarly, for
time-dependent drugs such as the b-lactams, CBPs are
heavily influenced by drug formulation. For example, a
CBP that is valid for oral tablets may not be valid for the
same drug administered by a long-acting intravenous for-
mulation, even if the total dose is the same. To overcome
this, several CBPs should be determined for a given sub-
stance depending on dose and formulation. However, this
approach would be very difficult to manage for diagnostic
companies and microbiology laboratories, because com-
mercial systems for AST should be implemented and vali-
dated for each CBP.
Currently no CBPs are available for topical antimicrobial
therapy, which is often used as a sole treatment in veteri-
nary dermatology, especially for management of otitis
externa. The relevance of AST for guiding topical antimicro-
bial therapy is questionable because CBPs are set for sys-
temic therapy, and the drug concentrations achieved in
serum by systemic administration are markedly lower than
those obtained by the topical route. Such concentrations
may exceed the MICs of skin pathogens greater than
100,000 fold (Table 3). These data suggest that infections
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Table 2. Bacteria for which host- and infection-specific clinical breakpoints exist in veterinary dermatology according to Clinical Laboratory
Standards Committee (CLSI).21 Drugs for which only human-derived breakpoints are available are highlighted in bold
Antibiotic
Animal/bacterial combinations for which clinical breakpoints for systemic treatment of skin
infections exist
Dogs Cats
Amoxicillin-clavulanic acid Escherichia coli, Staphylococcus spp. E. coli, Staphylococcus spp.,
Streptococcus spp.,
Pasteurella spp.
Ampicillin E. coli, Streptococcus canis, Staphylococcus
pseudintermedius
None*
Cefalothin E. coli, Staphylococcus aureus, S. pseudintermedius,
Streptococcus spp.
None*
Cefazolin E. coli, S. aureus, S. pseudintermedius,
Pasteurella multocida,
Streptococcus spp.
None*
Cefovecin None None
Cefpodoxime E. coli, S. aureus, S. pseudintermedius,
Pasteurella multocida,
Proteus mirabilis, Streptococcus spp.
None*
Chloramphenicol None* None*
Clindamycin Staphylococcus spp., Streptococcus spp. None*
Difloxacine Enterobacteriaceae, Staphylococcus spp. None*
Doxycycline Staphylococcus pseudintermedius None*
Enrofloxacin Enterobacteriaceae, Staphylococcus spp. None‡
Gentamicin None† None*
Marbofloxacin Enterobacteriaceae, Staphylococcus spp. None‡
Orbifloxacin Enterobacteriaceae, Staphylococcus spp. None‡
Pradofloxacin E. coli, S. pseudintermedius E. coli, S. pseudintermedius,
Staphylococcus felis,
Staphylococcus aureus,
S. canis, Pasteurella spp.
Rifampicin None* None*
Trimethoprim-sulfamethoxazole None* None*
Tetracycline Staphylococcus spp. None*
Ticarcillin  clavulanic acid None* None*
*Breakpoints (BP) from human medicine or another animal species are used instead.
†A generic BP exists for Enterobacteriaceae and Pseudomonas spp. in dogs, but this is not specific to any infection type.
‡A generic BP exists for skin and soft tissue infections in cats, but this is not specific to any bacterial species.
Table 3. Examples of antimicrobial concentrations in veterinary products for topical use and minimum inhibitory concentrations (MICs)
Active
compound
Examples of
topical products
containing compound
Concentration in
commercial
product (mg/L)* Reported MIC ranges (mg/L)
Reported
MIC90
(mg/L)
References
for MIC
ranges
Gentamicin Otomax Vet/EasOtic 4,119/2,348 Pseudomonas aeruginosa: 0.25–16 8 54
Miconazole EasOtic/Surolan Vet 13,100/19,970 Coagulase-positive staphylococci: 1–8 NA 55
Polymyxin B Surolan Vet 654 Coagulase-positive staphylococci: 0.25–64 NA 55
Fusidic acid Canaural 4,150 Coagulase-positive staphylococci: 0.06–1,024 0.5–4 56
Framycetin† Canaural 4,300 Coagulase-positive staphylococci: ≤0.5–64
P. aeruginosa: 8–1,024
NA
128–256
55
57
Mupirocin Muricin 20,000 Staphylococcus pseudintermedius: ≤0.03 to >1,024
Coagulase-positive staphylococci: 0.06–16
NA
0.125–1
58
56
Enrofloxacin Baytril Otic 5,000 P. aeruginosa: 0.015–32
P. aeruginosa: 0.125 to >64
32
NA
54
59
Florfenicol Osurnia 10,000 Escherichia coli: 1->64
S. pseudintermedius: 0.25–32
Staphylococcus spp: 2–32
Streptococcus spp.: 0.5->128
Proteus spp.: 4–16
Enterococcus spp.: 1–8
Pseudomonas spp.: >64
16
8
8
2->128
8
8
1,024
60
NA data not available.
*The concentrations stated for Canaural and Muricin represent mg/kg instead of mg/L.
†Framycetin is a synonym for neomycin B and MIC data are reported here for neomycin.
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caused by strains categorized as resistant by AST can be
treated successfully by topical therapy. However, this
hypothesis has not been validated clinically or experimen-
tally and needs to be supported by scientific evidence in
order to be translated into guidelines for antimicrobial use.
Detection of meticillin resistance in staphylococci
According to the MRSA expert rule, a S. aureus strain
found to be meticillin-resistant, as determined by oxa-
cillin, cefoxitin, or detection of mecA or its product
PBP2a, should be reported as resistant to all
b-lactams, except those that have been specifically
licensed to treat MRSA infections (e.g. ceftaroline and
ceftobiprole, which are not licensed for veterinary
use).46 This rule was established based on clinical and
microbiological evidence that MRSA strains display
cross-resistance to b-lactams used in clinical practice
for treatment of human staphylococcal infections. This
rule has been translated to veterinary medicine without
any clinical and/or microbiological evidence that MRSP
and meticillin-resistant S. schleiferi (MRSS) display
cross-resistance to the b-lactams used in veterinary
dermatology. Various factors suggest that this rule
may lead to reporting of false resistance to these
b-lactams in strains expressing low-level meticillin
resistance. A considerable proportion of MRSP strains
display oxacillin MICs (0.5–4 lg/mL) that are signifi-
cantly (2–8-fold) lower than the resistance breakpoint
for MRSA detection (R ≥ 4 lg/mL).47 This is why, simi-
larly to CoNS, the resistance breakpoint set for MRSP
detection is considerably lower compared to MRSA
(R ≥ 0.5 lg/mL).21 Cefalexin is one of the most active
cephalosporins against staphylococci and has been
associated with good clinical cure rates (90–100%) for
uncomplicated MRSA skin infections in humans.48,49
Studies have demonstrated that cephalosporin resis-
tance in CoNS, which display levels of meticillin resis-
tance comparable to those in MRSP, is dependent on
the degree of meticillin resistance expressed by the
strain.50 Lastly, amoxicillin and ampicillin have been
reported to have relatively good affinity for PBP2a, and
older in vivo studies claimed anti-MRSA efficacy of
high doses of aminopenicillins combined with b-lacta-
mase inhibitors for treatment of skin and soft tissue
infections, and urinary tract infections.51
Research to provide evidence to support this expert
rule in veterinary medicine is indicated. In the interim, the
authors recommend that any oxacillin-resistant staphylo-
cocci should be reported as resistant to all b-lactams
licensed for veterinary use. However, if therapy with
amoxicillin clavulanate or cefalexin has been initiated and
the causative strain has a low MIC of oxacillin, we recom-
mend evaluating the clinical outcome of therapy before
changing antimicrobial prescription. As already men-
tioned, AST has a limited predictive value for infections
caused by strains reported as resistant.44
Although the cefoxitin disk test is generally recognized
as reliable for MRSA detection, a recent study has shown
that cefoxitin may not be a good surrogate for MRSP detec-
tion by disk diffusion.47 In the absence of an internationally
recognized cefoxitin breakpoint clearly differentiating
mecA-positive from mecA-negative isolates of
S. pseudintermedius, we recommend that laboratories use
oxacillin disk or MIC tests for detection of meticillin resis-
tance in this and other staphylococcal species, other than
S. aureus.
Result reporting
Reporting of polymicrobial skin and wound culture results
is a challenge, especially when samples derive from con-
taminated sites. In these cases, the dominant colony type
(s) associated with micro-organisms of clinical relevance
should be selected or the report should outline that an
unspecific mixed growth with limited or no clinical rele-
vance was detected. Samples from ears also tend to be
polymicrobial. For these samples, the same principle of
reporting the dominant colony type should be used, but
additional factors complicate the decision of selection for
subculture and AST: (i) relatively few bacterial species (Pro-
teus spp. and Pseudomonas aeruginosa) are obligate
pathogens of canine ears, whereas other species also
occur in healthy dogs, hence the latter would only be rele-
vant in case of pure or almost pure culture; (ii) Corynebac-
terium auriscanis should not be selected for AST as it
seems clinically irrelevant and there is no CBP for this spe-
cies.52,53 Clinicians should consider the limited value of
AST for topical therapy when sampling ear infections and
when interpreting results obtained from diagnostic labora-
tories that indiscriminately report any type of growth.
Various measures such as selective or cascade report-
ing of AST results can be used by the microbiology labora-
tory to guide rational choice of antimicrobials. This
approach is used extensively in human hospitals to
encourage use of first-line drugs. The practice of not
reporting the results for selected agents is regarded as
selective reporting. For example, AST data should not be
reported for critically important drugs that are not
licensed for veterinary use (e.g. imipenem, vancomycin
and linezolid), even if these drugs are included in the
antimicrobial panel as last-resort agents for surveillance
purposes. Cascade reporting is the practice of reporting
the AST result for only one drug that tests susceptible
within a certain class (e.g. gentamicin within the amino-
glycosides) to reduce the use of more expensive and/or
broader spectrum drugs of the same class (e.g. amikacin).
In the absence of guidelines for selective or cascade
reporting, decisions should be made in consultation with
an infectious disease specialist. Linking the clinic to the
laboratory information management system to enable
data exchange and implementation of antimicrobial stew-
ardship programmes would be optimal.7 A variety of soft-
ware programmes are available on the market for
effective management of veterinary practices but they
are not designed to interact with the laboratory or are dif-
ficult to implement. It is desirable for manufacturing com-
panies to improve veterinary practice management
software in order to facilitate antimicrobial stewardship.
Conclusions
The microbiology laboratory should play an important
role in the diagnosis of infectious diseases by providing
key support to various steps of the diagnostic process,
from specimen collection and transportation to
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interpretation of AST results. The laboratory’s role and
responsibilities should extend beyond correct specimen
testing and reporting of results, and include guidance
in both the pre- and postanalytical phases of the diag-
nostic process. Furthermore, a good microbiology ser-
vice is essential for implementation of antimicrobial
stewardship programmes in veterinary practice.
The advent of MALDI-TOF MS in clinical microbiology
has significantly reduced the time required for bacterial ID
and facilitated ID of veterinary pathogens that previously
could not be identified. The concomitant developments in
genome sequencing technologies are improving our
understanding of the taxonomy, ecology and population
structure of key pathogens in veterinary dermatology
such as S. pseudintermedius and S. schleiferi. Despite
these technological advances, veterinary diagnostic
microbiology is still based predominantly on traditional
culture methods, and the turnaround time for AST has
essentially remained unchanged for many years. Meth-
ods for AST are not yet harmonized and clinical break-
points for important drug–pathogen combinations are
either missing or inadequate. Small veterinary microbiol-
ogy laboratories, including in-clinic laboratories, often nei-
ther have the infrastructure nor the expertise required to
run up-to-date clinical microbiology, and adequate post-
graduate training in veterinary clinical microbiology is not
available in most countries.
ESGVM recommends that diagnostic microbiology lab-
oratories are selected by veterinary practitioners taking
into consideration the following factors:
• Guidance for optimal specimen management (i.e.
selection, collection, storage and transportation of
clinical specimens).
• State-of-the-art methods for ID (MALDI-TOF- MS) and
AST (MIC determination by broth micro-dilution).
• Implementation of transparent and ongoing quality
assurance measures, preferably by accredited labo-
ratories
• Availability of skilled microbiologists for case-based
expert advice and data interpretation.
Other factors include the availability of a courier system
for overnight delivery of specimens to the laboratory, and
access to data for passive epidemiological surveillance
and implementation of antimicrobial stewardship pro-
grammes at the clinic level. Certification of veterinary
microbiologists at a national or, preferably, international
level should be a prerequisite. National accreditation,
such as according to ISO standards, should be obtained
to ensure minimum quality and safety standards.
ESGVM supports the development of PoC tests that
could rationalize antimicrobial use in veterinary practice, pro-
vided that (i) the performance of the test has been evalu-
ated scientifically, (ii) clinical staff are adequately trained to
interpret the results and (iii) clinics meet the minimal
requirements for handling microbiological specimens (bio-
safety level 1). There is concern about direct AST replacing
conventional AST due to the potential for error and the sub-
sequent selection of a drug that is not effective.
ESGVM has a mission to set standards for veterinary
clinical microbiology, including methods and training, and
the promotion of antimicrobial stewardship and construc-
tive interaction between microbiologists and clinicians.
The group promotes diagnostic microbiology in veterinary
practice by standardizing procedures and by educating
veterinarians about the key role played by microbiology
laboratories in antimicrobial stewardship and patient care.
ESGVM strongly supports (i) global harmonization of
methods and setting of infection-, animal- and bacterial-
specific CBPs for AST of veterinary pathogens; (ii) post-
graduate education and board certification of specialists
in veterinary clinical microbiology and antimicrobial stew-
ardship; (iii) official licensing of veterinary diagnostic
microbiology laboratories and quality assurance to guaran-
tee the minimum quality and biosafety standards required
to perform veterinary microbiology; and (iv) development
of new diagnostic tests providing veterinarians with rapid
and reliable results at reasonable cost.
ESGVM has supported the creation of VetCAST and
established an ESCMID postgraduate educational course
on Antimicrobial Stewardship in Veterinary Medicine
(https://www.escmid.org/index.php?id=1755).
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Resume
Contexte – Le laboratoire de microbiologie peut e^tre considere comme un fournisseur de service plus que
comme un partenaire a part entiere du parcours de soins.
Objectifs – Le but de cette revue est de discuter des defis actuels de fournir un service de microbiologie
veterinaire dans les regles de l’art comprenant l’identification (ID) et les tests de sensibilite antimicrobienne
(AST) des pathogenes cles en dermatologie veterinaire.
Methodes – L’ESGVM (Study Group for Veterinary Microbiology) de l’ESCMID (European Society of Clini-
cal Microbiology and Infectious Diseases) a identifie les omissions regulieres scientifiques, technologiques,
pedagogiques influant sur la valeur predictive de l’AST et la qualite de service offerte par les laboratoires de
microbiologie.
Resultats – Le developpement de la spectrometrie de masse a significativement reduit le temps neces-
saire a l’identification des pathogenes cles tels que Staphylococcus pseudintermedius. Cependant, le delai
de production pour des methodes d’AST validees reste inchange depuis plusieurs annees. Au-dela des
contraintes scientifiques et technologiques, les methodes d’AST ne sont pas harmonisees et les points de
rupture clinique pour certains antimicrobiens sont soit manquant soit inadaptes. Les petits laboratoires,
comprenant les laboratoires internes aux cliniques ne sont generalement pas equipe de facon adequat pour
realiser des tests diagnostiques microbiologiques cliniques actualises et adaptes.
Conclusions et importance clinique – L’ESGVM recommande l’utilisation de laboratoires utilisant la
spectrometrie de masse pour l’identification et la microdilution pour l’AST et offrant une assistance par des
experts microbiologistes sur les donnees pre et post analytiques. Les donnees generales standards pour la
microbiologie veterinaire clinique promouvant l’administration antimicrobienne, et le developpement de
methodes de diagnostic rapides, validees et nouvelles, en particulier pour l’AST font partie des missions de
l’ESGVM.
Resumen
Introduccion – El laboratorio de microbiologıa puede ser percibido como un proveedor de servicios en
lugar de ser una parte integral del equipo de salud.
Objetivos – El objetivo de esta revision es discutir los retos actuales de proporcionar un servicio de micro-
biologıa veterinaria de diagnostico de vanguardia, incluyendo la identificacion (ID) y la prueba de susceptibi-
lidad antimicrobiana (AST) de patogenos claves en dermatologıa veterinaria.
Metodos – El Grupo de Estudio de Microbiologıa Veterinaria (ESGVM) de la Sociedad Europea de Microbio-
logıa Clınica y Enfermedades Infecciosas (ESCMID) identifico omisiones cientıficas, tecnologicas, educati-
vas y regulatorias que afectan al valor predictivo de AST y a la calidad del servicio ofrecido por los
laboratorios de microbiologıa.
Resultados – La llegada de la espectrometrıa de masas ha reducido significativamente el tiempo requerido
para la identificacion de patogenos clave como Staphylococcus pseudintermedius. Sin embargo, el tiempo
de respuesta para los metodos AST validados se ha mantenido sin cambios durante muchos a~nos. Mas alla
de las limitaciones cientıficas y tecnologicas, los metodos AST no estan armonizados y los puntos de corte
clınicos para algunos farmacos antimicrobianos no estan determinados o son inadecuados. Los peque~nos
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laboratorios, incluidos los laboratorios dentro de las clınicas, generalmente no estan adecuadamente equi-
pados para realizar pruebas de diagnostico microbiologico clınico actualizadas.
Conclusiones e importancia clınica – ESGVM recomienda el uso de laboratorios que emplean espectro-
metrıa de masas para ID y micro-dilucion de caldo de cultivo para AST, y que ofrecen asistencia de
microbiologos expertos en cuestiones pre- y post-analıticas. Entre las misiones del ESGVM figuran el esta-
blecimiento de normas generales para la microbiologıa clınica veterinaria, la promocion de la administracion
antimicrobiana y el desarrollo de metodos de diagnostico nuevos, validados y rapidos, especialmente para
la AST.
Zusammenfassung
Hintergrund – Das Mikrobiologielabor ist eher als Dienstleister und nicht als ein integraler Bestandteil des
Gesundheitsteams zu betrachten.
Ziele – Das Ziel dieser Review ist eine Diskussion €uber die derzeitigen Herausforderungen ein State-of-the-
Art diagnostisches veterin€armikrobiologisches Service zu bieten, welches die Identifizierung (ID) und die
antimikrobiellen Empfindlichkeitstests (AST) der Schl€usselpathogene der Veterin€ardermatologie inkludiert.
Methoden – Die Forschungsgruppe f€ur Veterin€armikrobiologie (ESGVM) der European Society f€ur klinische
Mikrobiologie und Infekti€ose Erkrankungen (ESCMID) identifizierte wissenschaftliche, technologische,
erzieherische und angeordnete Weglassungen, welche den Vorhersagewert f€ur AST und die Qualit€at der
geleisteten Dienste durch die Mikrobiologielaboratorien beeinflusste.
Ergebnisse – Das Erscheinen der Massenspektrometrie hat die Zeit, die f€ur die ID der Schl€usselpathogene
wie Staphylococcus pseudintermedius n€otig ist, signifikant reduziert. Nichtsdestotrotz bleibt die Umlaufzeit
f€ur validierte AST Methoden seit vielen Jahren unver€andert. Neben wissenschaftlichen und technologi-
schen Grenzen sind die AST Methoden nicht harmonisiert und die klinischen Messpunkte f€ur einige antimi-
krobielle Wirkstoffe fehlen entweder oder sie sind nicht ad€aquat. Kleine Laboratorien, zu denen auch die
Laboratorien in den Kliniken geh€oren, sind normalerweise nicht ausreichend ausger€ustet, um klinische
mikrobiologische diagnostische Tests auf dem neuesten Stand durchzuf€uhren.
Schlussfolgerungen und klinische Bedeutung – Die ESGVM empfiehlt die Verwendung von Laborato-
rien, die die Massenspektrometrie zur ID und ein Mikrobouillon-Dilutionsverfahren f€ur AST einsetzen und
Unterst€utzung von Mikrobiologieexperten bei Problemen vor sowie nach der Analyse anbieten. Das Eta-
blieren von Allgemeinstandards f€ur die klinische Veterin€armikrobiologie, antimikrobiologische Verantwor-
tung zu f€ordern und die Entwicklung von neuen, validierten und raschen diagnostischen Methoden, vor
allem f€ur AST, sind unter anderem Ziele von ESGVM.
要約
背景 – 微生物検査機関は医療チームの不可欠な一員としてよりも、サービス提供機関として認識されて
いる。
目的 – 本総論では、獣医皮膚科領域で重要な病原体の細菌同定(ID)および抗菌剤感受性試験(AST)などを
含めた最新鋭の獣医微生物学診断サービスを提供するための現在の取り組みを紹介する。
方法 – ヨーロッパ臨床微生物感染症学会(ESCMID)の獣医細菌学研究会(ESGVM)によって、予想される
ASTの結果や微生物検査機関の提供サービスの質に影響を与えると考えられる科学的、技術的、教育的
および制御的遺漏が検証された結果質量分析法の出現により、Staphylococcus pseudintermediusなどの重要
な病原体のIDにかかる時間が大幅に軽減された。しかしながら、妥当なAST法に要する時間は長年変
わっていない。科学的およ技術的制約以外に、AST法は統一されておらず、いくつかの抗菌薬に対する
臨床的なブレイクポイントは存在しない、あるいは不適切である。院内検査機関を含めた小規模な検査
機関では、多くの場合、最新の臨床微生物診断検査を実施するための適切な設備を持っていない。
結論および臨床的な重要性 – ESGVMは、IDに質量分析法を、ASTにブロス微量希釈法を使用し、また、
解析前後の問題に対して専門の微生物学者の補佐を提供している検査機関を利用することを推奨する。
獣医臨床微生物学の準則の設定、抗菌剤管理責任の推進、そして、特にASTに対する妥当かつ迅速な新
たな診断法の確立がESGVMの役目である。
摘要
背景 – 微生物学实验室不是医疗团队的成员,但可以作为技术的提供者。
目的 – 本文在现有技术条件下,讨论兽医微生物学提供诊断时面临的挑战,其中包括动物皮肤病学的关键病
原的菌种鉴定(ID)和抗菌药物敏感性试验(AST)。
方法 – 欧洲临床微生物与传染病学会(ESCMID)的兽医微生物研究团队(ESGVM),确认微生物实验室的科学
性、技术性、教育和监管疏漏,可能对AST预测价值和服务质量的影响
结果 – 质谱法的出现大大缩短了关键病原的ID需要时间,例如假中间型葡萄球菌。但是,AST方法的大致时
间仍维持多年未变。脱离了科学和技术的制约,AST法不一致,并且一些抗菌药物的临床断点,不是错误的就
是不合理的。小型实验室,包括诊所内的化验室,通常配置无法跟进最新的临床微生物诊断技术。
结论和临床意义 – ESGVM推荐实验室使用质谱法测ID,对AST用肉汤微稀释法,并由微生物学专家提供帮助
分析前后问题。建立兽医临床微生物学的总标准,改进抗菌药的管理方式,尤其对于AST发展新的、有效和快
速的诊断方法,这些都涵盖在ESGVM的工作范畴中。
Guardabassi et al.
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Resumo
Contexto – O laboratorio de microbiologia pode ser tido como um prestador de servicos ao inves de uma
parte integral da area da saude.
Objetivos – O objetivo desta revis~ao e discutir os desafios atuais de fornecer um servico de diagnostico
em microbiologia veterinaria de alto padr~ao de qualidade, incluindo testes de identificac~ao (ID) e susceptibi-
lidade a antimicrobianos (SAM) de patogenos relevantes em dermatologia veterinaria.
Metodos – O Grupo de Estudos em Microbiologia Veterinaria (GEMV) da Sociedade Europeia de Microbio-
logia Clınica e Doencas Infecciosas (SEMCDI) identificou omiss~oes cientıficas, tecnologicas, educacionais
e regulatorias que impactam no valor preditivo de SAM e na qualidade dos servicos oferecidos pelos labo-
ratorios de microbiologia.
Resultados – O advento da espectrometria de massa reduziu significativamente o tempo requerido para
ID de patogenos importantes como Staphylococcus pseudintermedius. Entretanto, o tempo de processa-
mento necessario para SAM tem se mantido o sem alterac~oes ha anos. Alem de limitac~oes tecnologicas e
cientıficas, metodos de SAM n~ao s~ao harmonizados e os intervalos de suscetibilidade e resiste^ncia para
determinados antibioticos s~ao inadequados ou inexistentes. Laboratorios pequenos, incluindo os internos
de clınicas, s~ao geralmente inadequadamente equipados para processar testes microbiologicos atualiza-
dos.
Conclus~oes e importa^ncia clınica – SEMCDI recomenda o uso de laboratorios que utilizam espectrome-
tria de massa para ID e microdiluic~ao em caldo para SAM, e oferecam assiste^ncia de microbiologistas para
problemas pre e pos-analıticos. Desenvolver padronizac~ao para microbiologia veterinaria clınica, promover
regulac~ao e melhorias no uso de antimicrobianos e o desenvolvimento de novos metodos de diagnostico
rapidos e validados, especialmente para SAM, est~ao entre as func~oes de SEMCDI.
State-of-the-art of diagnostic microbiology
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